Sinoy Sugunan

Sinoy Sugunan

Auto-generated profile, based on publicly available information

Sinoy Sugunan

School of Biotechnology, National Institute of Technology Calicut, Calicut, India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2018 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
SSSujith Raj Salian
Sujith Raj Salian
GNGuruprasad Nayak
Guruprasad Nayak
SKSandhya Kumari
Sandhya Kumari
SPSandesh Patel
Sandesh Patel
SGShruthi Gowda
Shruthi Gowda
GKGuruprasad Kalthur
Guruprasad Kalthur

18 October 2016 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
SSSinoy Sugunan
Sinoy Sugunan
SNSreekala Nampoothiri
Sreekala Nampoothiri
TGTanya Garg
Tanya Garg
RKRajanikant G. K.
Rajanikant G. K.
KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.

21 May 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SSS. Sinoy
S. Sinoy
SFS. M. Fayaz
S. M. Fayaz
KCK. D. Charles
K. D. Charles
VSV. K. Suvanish
V. K. Suvanish
JKJosef Kapfhammer
Josef Kapfhammer
RKRajanikant G. K.
Rajanikant G. K.

7 December 2020 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
SKSandhya Kumari
Sandhya Kumari
SKSukumar Kotyan
Sukumar Kotyan
SSSinoy Sugunan
Sinoy Sugunan
GRG. K. Rajanikant
G. K. Rajanikant
SSSharath Kumar K S
Sharath Kumar K S
GKGuruprasad Kalthur
Guruprasad Kalthur
Poor sperm motility is one of the major causes of male infertility and fertilization failure in assisted reproductive technology (ART). Pentoxifylline (PTF), a phosphodiesterase inhibitor (PDEI), has been used previously in ART to enhance sperm motility. However, reports on its adverse effects on sperm function and early embryo development have resulted in a need to find safe alternative molecules. The aim of the present study was to synthesize various structurally modified pentoxifylline (mPTF) compounds and then screen them to determine if they possess a beneficial role in enhancing human sperm motility. A series of 3,7-dimethyl-1-[(6E)-5-oxo-7-aryllhept-6-en-1-yl]-3,7-dihydro-1H-purine-2,6-diones (mPTF1-mPTF6) was synthesized via treating PTF with various arylaldehydes in the presence of alcoholic KOH solution. The structures of the novel compounds were confirmed via Fourier transform infrared spectroscopy (FT-IR) (without the KBr method), 1H-NMR, 13C-NMR, and liquid chromatography (LC)-mass spectrometry studies. These compounds were screened for their human sperm motility enhancement properties. Among the six compounds, 1-[(6E)-7-(6-methoxynaphthyl)-5-oxohept-6-en-1-yl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione (mPTF1) exhibited superior motility enhancement and prolonged survival in vitro in comparison to PTF. The optimum activity of mPTF1 was observed at a concentration that was four times lower (0.25 mM) than the parent compound (1 mM), indicating its increased efficiency. Comparative cytotoxicity and genotoxicity assays revealed that mPTF1 has significantly lower genotoxicity than the parent molecule PTF. Overall, the results indicated that the structural modification of PTF can increase sperm motility and its longevity in vitro. The modification also resulted in reduced genotoxic effects. Therefore, mPTF1 may have better therapeutic potential than the parent compound PTF in ART.

1 March 2013 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
SSSinoy Sugunan
Sinoy Sugunan
DJDiya Binoy Joseph
Diya Binoy Joseph
GRG. K. Rajanikant
G. K. Rajanikant
Ischemic stroke is the leading cause of mortality and morbidity worldwide for which the assemblage of therapeutic interventions has remained outstandingly limited. Several new insights into the causes of neuronal death during ischemic event have led to the identification of some important novel targets for intervention. This article highlights some of the promising protein targets, which are in the validation process and have the potential to get translated into viable neurotherapeutics against ischemic stroke.

1 May 2013 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
RKRajanikant G. K.
Rajanikant G. K.
SSSinoy Sugunan
Sinoy Sugunan